68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

@article{Fendler201768GaPSMAPJ,
  title={68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0},
  author={Wolfgang Peter Fendler and Matthias Eiber and Mohsen Beheshti and Jamshed Bomanji and Francesco Ceci and Steven Cho and Frederik L. Giesel and Uwe Haberkorn and Thomas A. Hope and Klaus Kopka and Bernd Joachim Krause and Felix M. Mottaghy and Heiko Sch{\"o}der and John J. Sunderland and Simon Wan and Hans-J{\"u}rgen Wester and Stefano Fanti and Ken Herrmann},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2017},
  volume={44},
  pages={1014-1024}
}
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of 68Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice. 

Preliminary results of a 68Ga‐PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision‐making

The impact of 68Ga‐PSMA‐11 PET‐CT on the treatment plan and therapeutic response obtained for patients with prostate cancer presenting a recurrence with a low rising PSA is investigated.

Therapy assessment in prostate cancer using choline and PSMA PET/CT

This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.

Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer.

A case of a 72-year-old man with recently diagnosed adenocarcinoma of prostate, incidentally found to have pleomorphic sarcoma on the staging Ga-PSMA PET/CT is reported.

68Ga‐PSMA‐11 PET‐CT study in prostate cancer patients with biochemical recurrence and non‐contributive 18F‐Choline PET‐CT: Impact on therapeutic decision‐making and biomarker changes

The impact of 68Ga‐PSMA‐11 PET‐ CT (PSMA PET‐CT) upon the treatment plan and therapeutic response obtained for Prostate Cancer patients presenting an occult biochemical recurrence is investigated.

A New Type of Prostate Cancer Imaging: Will 64CuCl2 PET/CT Flourish or Vanish?

The use of 64CuCl2 as an alternative PET radiopharmaceutical for investigating recurrent prostate cancer is proposed in this issue of The Journal of Nuclear Medicine.

68Ga-PSMA-Avid Small Cell Lung Cancer on PET/CT: Incidental Second Malignancy in Treated Prostate Cancer.

  • P. Sharma
  • Medicine
    Clinical nuclear medicine
  • 2020
The case of a 59-year-old man, where a second primary metastatic small cell lung cancer was discovered on Ga-PSMA PET/CT done for suspected recurrence of prostate cancer, is presented.

Is it time to fund routine NHS usage of PSMA PET-CT?

There is a need for a technique that accurately stages patients presenting with high-risk localized or locally advanced disease and also enables early detection and localization of disease in patients with biochemical recurrence after radical treatment.

Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.

PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging, and both PET/CT and PET/MRI offer benefits with PSMA radiotracers.
...

References

SHOWING 1-10 OF 60 REFERENCES

68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

This experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence is summarized and includes relevant issues on free-text as well as structured reporting used in daily clinical routine.

First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT

The prostate-specific membrane antigen (PSMA) has recently emerged as a target for radionuclide imaging and therapy of prostate cancer, but no study has yet investigated its role in a number of other cancers.

68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.

A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with Ra.tech, which showed a clear response of bone metastases.

Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

The great potential of 68Ga-PSMA PET/CT in patients with rPCa and BR was confirmed and PSA and PSAdt were valuable predictors of pathological 68Ga/CT findings.

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

68Ga-PSMA-ligand PET/CT can detect recurrent PCa in a high number of patients and can help delay systemic therapy of PCa.

Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer

The results indicate that BS in patients who have received PSMA PET for staging only rarely offers additional information; however, prospective studies, including a standardized integrated x-ray computed tomography (SPECT/CT) protocol, should be performed in order to confirm the presented results.

Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer

PSMA-PET/CT and MP-MRI correlated well with regard to tumor allocation in patients with a high pre-test probability for large tumors, and further research will be needed to evaluate its value in challenging situation such as prostatitis or after repeated negative biopsies.

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

Both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.

Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT

The case of an 87-year-old man with a history of prostatic adenocarcinoma diagnosed in 2006 and initially treated locally with high intensity focused ultrasound is presented, where a non-expected overexpression of PSMA was found involving the proximal phalanx of the fourth finger of the left hand.
...